Medpace Holdings stock

MEDP · NASDAQ · USD

Compare Medpace Holdings
$653.09Change from previous close: +0.75%Absolute change: +$4.89

Close · November 17, 2026

Price history

+10.27% over the period

1 year: from $585.76 (November 17, 2025) to $645.90 (November 17, 2026), +10.27%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 2026$645.90
October 30, 2026$652.01
September 30, 2026$624.18
August 31, 2026$593.99
July 31, 2026$577.11
June 30, 2026$529.59
May 29, 2026$447.11
April 30, 2026$418.66
March 31, 2026$480.19
February 27, 2026$451.76
January 30, 2026$582.48
December 31, 2025$561.65
November 28, 2025$592.46
November 17, 2025$585.76

At a glance

  • The company

    Provides clinical research services supporting drug and medical device development from Phase I to Phase IV across multiple therapeutic areas

  • Latest results

    Quarter to September 30, 2026 · EPS $4.84 (estimate $4.44)

TickerLandia's take on Medpace Holdings

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$373.00
52-wk high$693.97

−5.89% from the 52-week high

Analysts · 14 analysts

Average target$651.31−0.27% vs. price

Buy 2 · Hold 11 · Sell 1

TickerLandia Fingerprint: Medpace Holdings

Compared with similar companies: very high profitability.

Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Medpace Holdings is pricier than in the past and in line with similar companies

On the latest fiscal year's earnings (2025), Medpace Holdings's P/E today is 42.3, above the median of its last 10 fiscal years (35.4; between 26.3 and 97.5 from 2016 to 2025). Medpace Holdings's P/E (trailing 12 months): 36.3, in line with the median of a group of 9 similar companies (36.3).

P/E compared with its history

Compared with 9 similar companies

Medpace Holdings's metrics compared with similar companies
MetricMedpace HoldingsPosition in the groupBand
P/E (trailing 12 months)36.3Middle
Forward P/E32.9High
Operating margin21.4%High
ROE117.9%High
Debt/equity0.29Low

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Medpace Holdings. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$716M

Latest quarter · Q3 2026

Net income

$137.46M

Latest quarter · Q3 2026

Quarterly net margin

19.2%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$18.27B
P/E
36.3
EPS
$18.01
Volume
175.85K
Daily trading
€177.03M
Dividend yield
0.00%

How Medpace Holdings is changing

All results
  • Revenue grew 22.3% a year on average over the last 5 years

  • Operating margin rose from 19.1% to 21.1%

  • Profits turn into cash: free cash flow equal to 145% of net income

Returns

Medpace Holdings returns

$1,000 invested in Medpace Holdings 5 years ago, on November 17, 2021, would be worth $2,840 today: +184.02% in total, +23.22% per year. This is the price return only: dividends are excluded.

PeriodMedpace HoldingsS&P 500$1,000 becomes
1 month+4.23%−3.17%$1,042
6 months+57.27%+0.11%$1,573
Year to date+15.00%+8.34%$1,150
1 year+10.27%+11.15%$1,103
3 years+135.72%+64.30%$2,357
5 years+184.02%+58.18%$2,840
10 years+1,701.17%+239.10%$18,012

Over the last 6 months it has done better than 92% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Medpace Holdings: technical analysis

Medpace Holdings is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 5.7% below its all-time closing high ($692.68, October 28, 2026).

Trend
Upward
RSI (14 sessions)
52
Between 30 and 70
vs 200-session average
+22.61%

Support and resistance

Price areas where Medpace Holdings has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$678.54+3.90%2 touches, last on November 9, 2026
  2. Last price$653.09
  3. Support$630.92−3.39%5 touches, last on November 5, 2026
  4. Support$567.46−13.11%3 touches, last on August 17, 2026
  5. Support$530.96−18.70%2 touches, last on April 16, 2026

Volatility and risk

Over the last year it has moved less than the S&P 500.

Beta (1 year) vs S&P 500
0.71
Volatility (60 sessions, annualised)
30.1%
Largest fall in the last year
−36.61%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Medpace Holdings: seasonality

Average monthly price change over 11 years

+0.6%Jan−3.5%Feb+0.7%Mar−0.8%Apr+2.5%May+8.5%Jun+14.2%Jul+3.2%Aug+0.1%Sep+5.6%Oct+5.8%Nov+2.5%Dec

Over the last 11 years, the strongest month for Medpace Holdings has been July: +14.23% on average, positive in 7 years out of 10. The weakest has been February: −3.54% on average, positive in 3 years out of 10. November, the current month, has been positive in 7 years out of 10 (+5.79% on average).

Show chart data
MonthAverageMedianPositive years
January+0.64%+1.53%6 of 10
February−3.54%−12.52%3 of 10
March+0.69%+2.39%7 of 10
April−0.77%+2.32%6 of 10
May+2.51%+1.45%5 of 10
June+8.54%+6.08%10 of 10
July+14.23%+11.12%7 of 10
August+3.25%+3.28%7 of 10
September+0.06%+3.80%7 of 11
October+5.64%+0.22%6 of 11
November+5.79%+6.27%7 of 10
December+2.52%+3.07%7 of 10

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Medpace Holdings and its competitors

Clinical trial work for drug and medical device developers is delivered across Australia, Africa, South America, Asia, Europe and North America. The company runs studies from Phase I through Phase IV for pharmaceutical, biotechnology and medical device sponsors active in a broad set of therapeutic areas. Its range covers study design, central laboratory coordination, regulatory submissions, post-marketing support, bio-analytical laboratory services, clinical pharmacology, imaging and electrocardiography reading for trials.

Headquarters
Cincinnati, United States
Employees
6,600
Founded
1992
Chief executive
August Troendle
Medpace Holdings and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Medpace HoldingsMEDP$18.27B21.4%36.3+57.27%
RevvityRVTY$17.84B16.3%70.5+57.27%
Guardant HealthGH$20.52B-39.4%—+50.95%
Charles River Laboratories InternationalCRL$16.19B14.3%367.4+120.19%
ICON PublicICLR$14.58B2.7%77.9+67.57%
Quest DiagnosticsDGX$28.85B14.9%26.1+37.37%

Same industry or related industries, similar size. Compare Medpace Holdings with its competitors · Full profile